A study was conducted to compare cardiovascular outcomes for single-pill antihypertensive combination therapy and identical multiple pill therapy. Risk for CV events and all-cause mortality is ...

Please provide your email address to receive an email when new articles are posted on . Pembrolizumab plus axitinib continued to exhibit superior efficacy to sunitinib as first-line therapy for ...

Bottom Line: Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical ...

Please provide your email address to receive an email when new articles are posted on . Hepatocellular carcinoma accounts for approximately 90% of all primary liver cancer cases, according to Zhen-Wei ...

A new report outlines helpful strategies for pediatric patients with pulmonary arterial hypertension, although experts say more research is needed to catch up with advances in the field. Children with ...

An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft ...

Derek van Amerongen, MD, MS: One of the important topics of discussion within a health plan, whenever we’re discussing treatment A versus treatment B, especially at the P&T discussions, is, what does ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, ...

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney disease and improve health outcomes. The findings could help guide more ...

Combination treatment with two PD-1 inhibitors — Yervoy and Opdivo — did not improve survival without cancer recurrence compared with Opdivo alone in patients with high-risk melanoma, a type of skin ...